摘要
目的:分析射频消融联合经导管肝动脉化疗栓塞术治疗原发性肝癌的效果。方法:2016年6月-2019年6月收治原发性肝癌患者80例,按术式不同分为两组,各40例。对照组采用射频消融术治疗;观察组采用射频消融联合经导管肝动脉化疗栓塞术治疗。比较两组治疗效果。结果:观察组远处转移发生率低于对照组,1年生存率高于对照组,差异有统计学意义(P<0.05);观察组治疗后甲胎蛋白、血清胎盘生长因子(PLGF)、异常凝血酶原(PIVKA-Ⅱ)等指标水平均低于对照组,差异有统计学意义(P<0.05)。结论:射频消融联合经导管肝动脉化疗栓塞术治疗原发性肝癌,可以控制癌症转移,提升患者生存期,且不会增加不良反应,改善临床指标水平。
Objective:To analyze the effect of radiofrequency ablation combined with transcatheter hepatic arterial chemoembolization in the treatment of primary liver cancer.Methods:From June 2016 to June 2019,80 cases of patients with primary liver cancer were enrolled,they were divided into two groups according to different operative methods,with 40 cases in each group.The control group was treated with RAF.The observation group was treated with RAF combined with TACE.The therapeutic effects between the two groups was compared.Results:The incidence of distant metastasis in the observation group was lower than that in the control group,the 1-year survival rate was higher than the control group,the differences were statistically significant(P<0.05).The levels of alpha fetoprotein,serum placental growth factor(PLGF)and abnormal prothrombin(PIVKA-Ⅱ)in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Radiofrequency ablation combined with transcatheter hepatic artery chemoembolization in the treatment of primary liver cancer can control cancer metastasis,improve the survival time of patients and the level of clinical indicators,and do not increase adverse reactions.
作者
吕超
李恒平
丁正华
孔雕雕
Lv Chao;Li Hengping;Ding Zhenghua;Kong Diaodiao(Graduate Student Training Base,Hubei Medical College,Jinzhou Medical University,Hubei Xiangyang 441000;Department of General Surgery,Xiangyang First People's Hospital Affiliated to Hubei Medical College,Hubei Xiangyang 441000)
出处
《中国社区医师》
2021年第17期45-46,共2页
Chinese Community Doctors
关键词
经导管肝动脉化疗栓塞术
射频消融
原发性肝癌
转移率
生存率
临床指标
Transcatheter hepatic artery chemoembolization
Radiofrequency ablation
Primary liver cancer
Metastasis rate
Survival rate
Clinical indicators
